The year is 2030. The world has changed, and the NHS has changed
with it. We’re following Sarah’s journey. Wearable technology monitors our health. This secure data is routinely shared with
the NHS and used alongside genomic profiling to build a picture of our population’s health. Sarah’s wearable tech identifies some unusual
symptoms, uses an algorithm to match them against risk
factors from her genomic profile and highlights this to Sarah, who arranges a video appointment, with an
NHS GP. The GP calls Sarah, with access to her full
medical records, genomic profile and wearable device data. The GP confirms the need for further investigation and refers Sarah to a diagnostic test centre. Sarah sees a specialist nurse at a genomic
medicine centre where they also have counselling and support
services. These specialists process the results of Sarah’s
test whilst she waits. The test identifies that the Sarah has an
early stage cancer. Specialists who understand the specific genetic mutations responsible for causing this cancer chat to Sarah and agree a treatment plan. A medicine is manufactured specifically to
target her cancer. Sarah’s treatment and response are monitored by a specialist multi-disciplinary team remotely. The information gathered shows the NHS how
this treatment works in the real-world. Sarah’s personalised treatment is successful
and her cancer goes into remission. Sarah’s specialists and GP continue to monitor
her symptoms remotely to identify any relapse and build evidence
of how her treatment worked. In time, Sarah returns to good health. This vision be a reality. Roche Products is calling on the NHS and its
partners to lead a conversation with the public about how we can realise the full potential of our new science and technology in the UK
health service.